omeprazole has been researched along with cox 189 in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Langholff, W; Milosavljev, S; Rordorf, C; Scott, G; Shenouda, M; Vinluan Reynolds, C | 1 |
| Albert, J; Arulmani, U; Bolten, W; Ell, C; Fortun, P; Hawkey, CJ; Hugot, JL; Keuchel, M; Krammer, G; McAlindon, M; Rebuli, R; Schumann, S; Shonde, A; Simon, B; Toth, E; Yu, V | 1 |
1 review(s) available for omeprazole and cox 189
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for omeprazole and cox 189
| Article | Year |
|---|---|
Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib.
Topics: Adolescent; Adult; Aluminum Hydroxide; Antacids; Area Under Curve; Cross-Over Studies; Cyclooxygenase 2; Diclofenac; Drug Combinations; Enzyme Inhibitors; Female; Humans; Isoenzymes; Magnesium Hydroxide; Male; Membrane Proteins; Middle Aged; Omeprazole; Organic Chemicals; Prostaglandin-Endoperoxide Synthases; Proton Pump Inhibitors | 2004 |
Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole.
Topics: Administration, Oral; Adult; Aged; Capsule Endoscopes; Cross-Over Studies; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Female; Humans; Intestinal Mucosa; Intestine, Small; Male; Middle Aged; Naproxen; Omeprazole; Probability; Reference Values; Risk Assessment; Ulcer | 2008 |
1 other study(ies) available for omeprazole and cox 189
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |